ibrutinib,venetoclax
janssen,abbvie,roche
['ibru', 'leukemia']
new imbruvica (ibrutinib) data in fixed-duration combination regimen presented at eha 2022 shows deep, durable response at three years in untreated chronic lymphocytic leukemia 
World's largest global Connected Community(tm) focused on HEOR, RWE and Market Access. Digital Channel owned by https://t.co/ZmJWTEwfNA.